Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Omvoh Market Value Growth And Long-Term Outlook
Historical growth was primarily propelled by progress in inflammatory bowel disease research and a rise in ulcerative colitis diagnoses. Further contributing factors include the expansion of biologic infusion infrastructure, improved clinical trial outcomes for IL-23 inhibitors, and increasing access to specialist gastroenterology care.
The anticipated growth throughout the forecast period is driven by the wider acceptance of targeted immunology therapies, the expansion of biologic maintenance treatment options, a heightened emphasis on steroid-sparing regimens, increased investments in the development of inflammatory disease drugs, and continuous innovation within monoclonal antibody platforms.
Noteworthy trends expected during the forecast period involve a greater uptake of IL-23 targeted biologic therapies, an intensified focus on precision treatment for IBD, the broadening of combination induction and maintenance regimens, an increase in the application of injectable monoclonal antibodies, and improved monitoring of how patients respond to treatment.
Get A Free Sample Report With In-Depth Market Insights:
Omvoh Market Growth Factors: What’s Supporting Expansion?
The increasing prevalence of autoimmune diseases is anticipated to propel the expansion of the Omvoh market. Autoimmune conditions involve the immune system mistakenly attacking the body’s healthy tissues, cells, or organs, rather than its intended targets like infections. Factors such as genetic predispositions, lifestyle choices, hormonal shifts, and an aging population contribute to this surge in autoimmune disorders. Omvoh assists patients by re-establishing immune equilibrium, counteracting detrimental antibodies, offering passive immunity, easing symptoms, diminishing inflammation, and guarding against further tissue damage associated with these diseases. For example, data from July 2024, provided by the National Health Service (NHS) England, a UK-based government department, indicates that multiple sclerosis affects over 150,000 individuals across the UK, with over 120,000 of them residing in England, and is observed more frequently in women. Approximately 135 new diagnoses are identified weekly, underscoring its considerable impact. Consequently, the escalation of autoimmune diseases will be a key driver for the Omvoh market’s growth.
Omvoh Market Segment Outlook: Which Categories Are Growing Fastest?
The omvoh market covered in this report is segmented –
1) By Formulation: Tablets Or Capsules, Injectables
2) By Clinical Indication: Ulcerative Colitis (UC), Crohn’s Disease, Psoriasis, Other Inflammatory Diseases
3) By End-User: Hospitals And Clinics, Pharmacies, Research Institutions
Omvoh Market Industry Trends: What’s Reshaping Demand?
Leading companies in the Omvoh market are prioritizing the development of innovative solutions, including advanced interleukin-23p19 (IL-23p19) antagonists, to address the increasing demand for targeted autoimmune therapies that offer deeper inflammation management and better long-term patient results. IL-23p19 antagonists operate by blocking the p19 subunit of the IL-23 cytokine, thereby reducing inflammatory signaling and presenting a more selective and potentially better-tolerated alternative to broader immunosuppressive treatments. For instance, in December 2024, Eli Lilly and Company, a US-based pharmaceutical company, announced that Omvoh received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for approval in the European Union for treating adults with moderately to severely active Crohn’s disease. This recommendation is underpinned by data from the Phase 3 VIVID-1 trial, which demonstrated significant improvements in clinical and endoscopic outcomes when compared to both placebo and an active control.
Omvoh Market Leading Companies And Competitive Benchmarking
Major companies operating in the omvoh market are Eli Lilly and Company
View The Full Omvoh Market Report:
Omvoh Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the omvoh market in 2025. The regions covered in the omvoh market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
